History

ARA-290 grew out of work by Anthony Cerami and Michael Brines on erythropoietin's tissue-protective role, separate from its blood-making job. In 2004 their group reported EPO derivatives that protected tissue without raising red cells (Science 2004) and proposed a distinct repair receptor (PNAS 2004). In 2008 they defined the helix-B surface peptide that became ARA-290 (PNAS 2008). Small Phase 2 trials in sarcoidosis neuropathy and diabetes followed (2013–2017), with EU orphan status in 2013 and US orphan/fast-track in 2016. No Phase 3 has been initiated.

ARA-290, also called cibinetide, is an experimental peptide built from a small piece of erythropoietin (EPO) — the hormone best known for telling your body to make red blood cells. The idea behind ARA-290 is to keep EPO’s tissue-repair and anti-inflammatory effects while stripping away the blood-building part. It has been tested in a handful of small human trials for nerve damage, and the early results are real but limited. There is no approved product anywhere in the world, and nearly all of the positive human data comes from the same group of researchers tied to the company developing it.

What it is

ARA-290 is a short, synthetic peptide — just 11 amino acids — that reproduces the outward-facing surface of one region (helix B) of erythropoietin. Its full sequence is pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Because it copies only a surface patch rather than the whole hormone, it lacks the part of EPO needed to trigger red-blood-cell production.

The proposed mechanism rests on the idea that EPO has two separate jobs handled by two different receptors. One receptor (the classic EPO receptor, working as a pair) drives red-cell production. The other — described by the developers as an “innate repair receptor,” a complex of the EPO receptor joined with the β-common receptor (CD131) — is said to deliver tissue protection, reduced inflammation, and cell survival. ARA-290 was engineered to engage this repair receptor while leaving the blood-building receptor untouched.

It is worth being clear-eyed here: the “innate repair receptor” concept comes largely from one research lineage (Brines, Cerami, and collaborators), and the exact makeup of that receptor complex has been debated in the broader EPO literature rather than settled. A 2016 study suggested ARA-290 may relieve pain partly through the TRPV1 channel. These are mechanistic findings in cells and animals — a plausible, developer-driven hypothesis with supportive lab data, not established fact and not proof of benefit in people.

The claims

In legitimate clinical research, ARA-290 has been studied for a narrow set of conditions: small-fiber neuropathy and neuropathic pain associated with sarcoidosis (the lead program), painful diabetic neuropathy with metabolic measures in type 2 diabetes, and diabetic macular edema (a small eye study). In animals and cell models it has been explored across a wide range of tissue-injury settings — stroke, kidney injury, heart protection, wound healing, and more — but those remain preclinical.

Separately, peptide vendors and “longevity” or biohacking sites promote ARA-290 for general “nerve repair,” “anti-inflammation,” “tissue healing,” and recovery. These marketing claims stretch far beyond what the trials actually tested, which was specific neuropathy populations over short periods (mostly 28 days). Many such pages also publish dosing instructions; those are not supported by any regulatory approval and fall outside legitimate medical use.

The evidence

There is genuine human trial data, but it is small, short, early, and heavily conflicted.

The most important study is a Phase 2b randomized controlled trial in sarcoidosis-associated small-fiber neuropathy (published 2017, registered as NCT02039687). It enrolled 64 patients across placebo and three doses (1, 4, and 8 mg by subcutaneous injection daily for 28 days). It met its prespecified primary endpoint at the 4 mg dose: placebo-corrected corneal nerve fiber area improved by 697 µm² (P=0.012), while the 1 mg and 8 mg doses were not statistically significant — an unusual, non-monotonic dose response where the middle dose outperformed the highest. A measure of regenerating skin nerve fibers (GAP-43+) also increased at 4 mg (P=0.035). Notably, overall pain change was not statistically significant.

An earlier sarcoidosis pilot RCT (2013) reported reduced neuropathic pain and increased corneal nerve fiber density. A Phase 2 trial in type 2 diabetes (2014) using 4 mg daily for 28 days reported improvements in HbA1c, lipids, and a pain questionnaire, with the authors stating no safety concerns were identified.

The picture is not uniformly positive. A very small Phase 2 trial in diabetic macular edema (2020, roughly 8–9 patients, 12 weeks) was negative on its main objective measures — no improvement in visual acuity, retinal thickness, retinal sensitivity, or tear production — with only a patient-reported quality-of-life questionnaire improving.

What is missing matters as much as what exists:

No Phase 3. There has been no pivotal, adequately powered, multi-center confirmation.
No independent replication. The positive human trials share the same core investigators and developer (Araim; Brines, Cerami, and Dahan recur as authors) — a significant conflict-of-interest concern.
Surrogate endpoints. Primary outcomes are nerve-fiber measurements and symptom questionnaires, not hard clinical outcomes or long-term function.
Tiny, brief studies. The largest trial had 64 patients; total published human exposure is roughly 100 people, mostly dosed for 28 days.
No independent systematic review. Available reviews are narrative and authored by the same developer-affiliated group.

Animal and mechanistic work is broader and supportive — including long-lasting pain relief in rats with suppression of the spinal microglia response — but supportive preclinical data is not confirmatory.

Safety and side effects

Across the small published trials, ARA-290 was generally well tolerated at subcutaneous doses up to 4–8 mg per day for 28 days (12 weeks in the tiny eye study). The most commonly described effects were mild, transient injection-site reactions and occasional mild headache. No serious adverse events were attributed to the drug, and the macular edema study reported no anti-cibinetide antibodies.

A central design rationale is that, because ARA-290 does not activate the blood-building EPO receptor, it is not expected to cause the classic hazards of EPO and related drugs — excess red cells (polycythemia), blood clots, or high blood pressure. This is an expectation backed by preclinical data, not a guarantee proven in large human populations.

The limitations are serious. The entire safety record rests on around 100 patients, almost all studied for 28 days or less, all in monitored trials, all developer-affiliated. Long-term and chronic-use safety is unknown. Effects in pregnancy, alongside other conditions, or with unregulated gray-market material — where identity, purity, dose, and contaminants are uncharacterized — are entirely unknown. The absence of reported harm in tiny, short trials is not evidence of long-term safety.

Legal and regulatory status

ARA-290 (cibinetide) is investigational only. It is not approved by the FDA, the EMA, or any other regulator for any indication anywhere in the world.

In the United States it holds Orphan Drug and Fast Track designations for neuropathic pain in sarcoidosis (orphan status reported July 2016). In the European Union it holds orphan designation EU/3/13/1191, granted 7 October 2013 for sarcoidosis, with sponsorship transferred to a Dublin-based entity in 2019. These designations are development incentives — they are not marketing approvals, and no approved product exists.

For competitive athletes, ARA-290 is not named explicitly on the WADA Prohibited List, but it is a non-erythropoietic EPO-derived agent. WADA’s Section S2 prohibits EPO-receptor agonists and, under S2.1.5, “innate repair receptor agonists” (with asialo-EPO and carbamylated EPO given as named examples), plus a catch-all for substances with similar structure or biological effect. On that basis ARA-290 is best treated as prohibited at all times under S2 by class, even though it is not named individually.

Because there is no approval and no active prescription pathway, what is sold online is “research-use-only” or “not for human consumption” material of unverified identity, purity, and dose — outside any regulatory oversight.

Bottom line

ARA-290 is one of the more scientifically interesting investigational peptides: a clever attempt to separate EPO’s tissue-repair effects from its blood-building effects. The human data is real — including a Phase 2b trial in sarcoidosis neuropathy that met its primary nerve-fiber endpoint — which puts it above purely animal-stage compounds. But that data is also small, short, built on surrogate endpoints, almost entirely produced by the developer’s own group, and accompanied by at least one clearly negative trial. There is no Phase 3, no independent replication, and no approval anywhere. The honest grade is preliminary human: promising signals that have not been confirmed. Anyone encountering ARA-290 sold for “nerve repair” or general recovery is looking at marketing that runs well ahead of the evidence.

ARA-290 (Cibinetide): A Non-Blood-Building EPO Fragment With Early, Conflicted Human Data